This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oleksowicz, L. Articles by DeLeon-Fernandez, M. Search for Related Content PubMed PubMed Citation Articles by Oleksowicz, L. Articles by DeLeon-Fernandez, M.

Deficient Activity of von Willebrand’s Factor-cleaving Protease in Patients with Disseminated Malignancies¹

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263 [L. O.]; and Department of Oncology, Montefiore Hospital and Albert Einstein Cancer Center, Bronx, New York [N. B., M. D-L.]

An aberrant platelet immunorelated glycoprotein Ib (GPIb) receptor expressed by human tumor cells appears to participate in primary adhesive interactions required for the metastatic process. Hence, we questioned whether plasma von Willebrand’s factor (vWf), its adhesive ligand, manifested comparable anomalies in patients with disseminated tumors. Plasma specimens from patients with disseminated metastases showed 68% (P < 0.013), 91% (P < 0.0009), and 207% (P < 0.0009) enhancements in FVIII:C activity, vWf-related antigen levels, and ristocetin cofactor activity, respectively, whereas their SDS-agarose electrophoretic analysis demonstrated a 165% (P < 0.001) increase in the highly polymeric forms of vWf compared to control preparations from patients with corresponding, localized solid tumors. Substantially reduced levels of vWf-cleaving protease activity were observed in study patient specimens, with no plasma inhibitors detectable. The clinical presence and absence of tumor metastases correlated significantly with vWf-cleaving enzyme activities of 15% and 88%, respectively (n = 20; P < 0.0001). Finally, with an in vitro model system, tumor-induced platelet aggregation was enhanced by 127% (P < 0.001) in study patient platelet-rich plasma (PRP) compared to control PRP and could be completely inhibited (P < 0.0009) when both tumor cells and their PRP substrates were incubated with monoclonal antibodies directed against the vWf binding epitope of GPIb and against the GPIb binding epitope of plasma vWf, respectively. Unusually large vWf multimers observed in patients with disseminated tumors probably result from deficient vWf-cleaving protease activity and may represent a novel mechanism regulating primary platelet-tumor adhesive interactions involved in the metastatic process.

This article has been cited by other articles:

				N. Goldenberg, S. R. Kahn, and S. Solymoss Markers of Coagulation and Angiogenesis in Cancer-Associated Venous Thromboembolism J. Clin. Oncol., November 15, 2003; 21(22): 4194 - 4199. [Abstract] [Full Text] [PDF]

				S. Savasan, S.-K. Lee, D. Ginsburg, and H.-M. Tsai ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity Blood, June 1, 2003; 101(11): 4449 - 4451. [Abstract] [Full Text] [PDF]

				H.-M. Tsai Advances in the Pathogenesis, Diagnosis, and Treatment of Thrombotic Thrombocytopenic Purpura J. Am. Soc. Nephrol., April 1, 2003; 14(4): 1072 - 1081. [Abstract] [Full Text] [PDF]

				H.-M. Tsai Platelet Activation and the Formation of the Platelet Plug: Deficiency of ADAMTS13 Causes Thrombotic Thrombocytopenic Purpura Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 388 - 396. [Abstract] [Full Text] [PDF]

				R. A. Reiter, P. Knobl, K. Varadi, and P. L. Turecek Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin Blood, February 1, 2003; 101(3): 946 - 948. [Abstract] [Full Text] [PDF]

				H.-M. Tsai, B. Lammle, V. Bianchi, L. Alberio, M. Furlan, G. Remuzzi, M. Galbusera, and P. M. Mannucci Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura Blood, November 15, 2002; 100(10): 3839 - 3842. [Full Text] [PDF]

				J. L. Moake Thrombotic Microangiopathies N. Engl. J. Med., August 22, 2002; 347(8): 589 - 600. [Full Text] [PDF]

				V. Bianchi, R. Robles, L. Alberio, M. Furlan, and B. Lammle Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura Blood, June 28, 2002; 100(2): 710 - 713. [Abstract] [Full Text] [PDF]

				P. M. Mannucci, M. T. Canciani, I. Forza, F. Lussana, A. Lattuada, and E. Rossi Changes in health and disease of the metalloprotease that cleaves von Willebrand factor Blood, November 1, 2001; 98(9): 2730 - 2735. [Abstract] [Full Text] [PDF]

				A. Veyradier, B. Obert, A. Houllier, D. Meyer, and J.-P. Girma Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases Blood, September 15, 2001; 98(6): 1765 - 1772. [Abstract] [Full Text] [PDF]

				J. N. George How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Blood, August 15, 2000; 96(4): 1223 - 1229. [Abstract] [Full Text] [PDF]